1. Home
  2. AIMD vs ENSC Comparison

AIMD vs ENSC Comparison

Compare AIMD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIMD
  • ENSC
  • Stock Information
  • Founded
  • AIMD 1984
  • ENSC 2003
  • Country
  • AIMD United States
  • ENSC United States
  • Employees
  • AIMD N/A
  • ENSC N/A
  • Industry
  • AIMD Biotechnology: Pharmaceutical Preparations
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIMD Health Care
  • ENSC Health Care
  • Exchange
  • AIMD Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • AIMD 8.5M
  • ENSC 7.9M
  • IPO Year
  • AIMD N/A
  • ENSC N/A
  • Fundamental
  • Price
  • AIMD $0.74
  • ENSC $5.80
  • Analyst Decision
  • AIMD
  • ENSC
  • Analyst Count
  • AIMD 0
  • ENSC 0
  • Target Price
  • AIMD N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • AIMD 379.0K
  • ENSC 53.4K
  • Earning Date
  • AIMD 03-07-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • AIMD N/A
  • ENSC N/A
  • EPS Growth
  • AIMD N/A
  • ENSC N/A
  • EPS
  • AIMD N/A
  • ENSC N/A
  • Revenue
  • AIMD $40,633.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • AIMD N/A
  • ENSC $89.78
  • Revenue Next Year
  • AIMD N/A
  • ENSC N/A
  • P/E Ratio
  • AIMD N/A
  • ENSC N/A
  • Revenue Growth
  • AIMD N/A
  • ENSC 40.41
  • 52 Week Low
  • AIMD $0.40
  • ENSC $2.12
  • 52 Week High
  • AIMD $3.10
  • ENSC $14.85
  • Technical
  • Relative Strength Index (RSI)
  • AIMD 59.44
  • ENSC 38.42
  • Support Level
  • AIMD $0.57
  • ENSC $5.34
  • Resistance Level
  • AIMD $0.77
  • ENSC $6.46
  • Average True Range (ATR)
  • AIMD 0.06
  • ENSC 0.45
  • MACD
  • AIMD -0.00
  • ENSC -0.07
  • Stochastic Oscillator
  • AIMD 68.48
  • ENSC 20.08

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: